SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 99,000
+4,200 (4.43%)
At close: Apr 1, 2026
SK Biopharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 706,741 | 547,596 | 354,892 | 246,179 | 418,645 |
Other Revenue | - | - | -0 | -0 | - |
| 706,741 | 547,596 | 354,892 | 246,179 | 418,645 | |
Revenue Growth (YoY) | 29.06% | 54.30% | 44.16% | -41.20% | 1510.23% |
Cost of Revenue | 42,901 | 43,101 | 34,082 | 37,768 | 22,336 |
Gross Profit | 663,840 | 504,495 | 320,809 | 208,411 | 396,309 |
Selling, General & Admin | 267,578 | 228,744 | 204,313 | 201,258 | 172,875 |
Research & Development | 174,344 | 161,270 | 137,126 | 122,817 | 114,526 |
Amortization of Goodwill & Intangibles | 3,820 | 6,017 | 5,758 | 5,055 | 4,251 |
Other Operating Expenses | 5,811 | 5,380 | 4,458 | 3,855 | 3,692 |
Operating Expenses | 459,901 | 408,156 | 358,331 | 339,489 | 301,350 |
Operating Income | 203,938 | 96,340 | -37,522 | -131,078 | 94,958 |
Interest Expense | -7,691 | -10,683 | -8,280 | -3,717 | -946.98 |
Interest & Investment Income | 7,085 | 10,146 | 9,317 | 6,755 | 2,343 |
Earnings From Equity Investments | -34,307 | -31,253 | -11,535 | -14,927 | -83,813 |
Currency Exchange Gain (Loss) | -5,977 | 16,706 | 1,026 | 8,878 | 11,985 |
Other Non Operating Income (Expenses) | -9,810 | -7,435 | -2,281 | -5,338 | -4,724 |
EBT Excluding Unusual Items | 153,238 | 73,820 | -49,274 | -139,427 | 19,803 |
Gain (Loss) on Sale of Investments | -2,757 | -1,396 | 12,243 | -2,858 | 51,477 |
Gain (Loss) on Sale of Assets | -194.81 | 171.02 | -18.72 | -11.28 | -3.02 |
Asset Writedown | 597.33 | - | -6,808 | -172.96 | - |
Pretax Income | 150,884 | 72,596 | -43,858 | -142,469 | 71,277 |
Income Tax Expense | -102,370 | -154,378 | -8,478 | -3,038 | 6,431 |
Earnings From Continuing Operations | 253,254 | 226,973 | -35,379 | -139,431 | 64,846 |
Net Income to Company | 253,254 | 226,973 | -35,379 | -139,431 | 64,846 |
Minority Interest in Earnings | 13,697 | 13,765 | 2,497 | - | - |
Net Income | 266,950 | 240,738 | -32,883 | -139,431 | 64,846 |
Net Income to Common | 266,950 | 240,738 | -32,883 | -139,431 | 64,846 |
Net Income Growth | 10.89% | - | - | - | - |
Shares Outstanding (Basic) | 78 | 78 | 78 | 78 | 78 |
Shares Outstanding (Diluted) | 78 | 78 | 78 | 78 | 78 |
Shares Change (YoY) | - | - | - | - | 9.12% |
EPS (Basic) | 3408.75 | 3074.04 | -419.89 | -1780.43 | 828.03 |
EPS (Diluted) | 3408.75 | 3074.04 | -419.89 | -1780.43 | 828.03 |
EPS Growth | 10.89% | - | - | - | - |
Free Cash Flow | 169,442 | 93,505 | -96,586 | -164,831 | -97,188 |
Free Cash Flow Per Share | 2163.64 | 1193.98 | -1233.34 | -2104.77 | -1241.01 |
Gross Margin | 93.93% | 92.13% | 90.40% | 84.66% | 94.66% |
Operating Margin | 28.86% | 17.59% | -10.57% | -53.24% | 22.68% |
Profit Margin | 37.77% | 43.96% | -9.27% | -56.64% | 15.49% |
Free Cash Flow Margin | 23.97% | 17.08% | -27.22% | -66.96% | -23.21% |
EBITDA | 220,886 | 113,767 | -22,205 | -118,094 | 106,600 |
EBITDA Margin | 31.25% | 20.78% | -6.26% | -47.97% | 25.46% |
D&A For EBITDA | 16,947 | 17,428 | 15,317 | 12,984 | 11,642 |
EBIT | 203,938 | 96,340 | -37,522 | -131,078 | 94,958 |
EBIT Margin | 28.86% | 17.59% | -10.57% | -53.24% | 22.68% |
Effective Tax Rate | - | - | - | - | 9.02% |
Advertising Expenses | 63,848 | 44,487 | 38,926 | 48,476 | 38,775 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.